ROS1 and non-small cell lung carcinoma: Although most studies comparing EVs and cf-DNA monitored the presence of mutations in a single gene (e.g., EGFR or BRAF) by PCR, more comprehensive genetic testing to identify less common targetable alterations in BRAF, ROS1, RET, NTRK, MET, and ERBB2 could also improve outcomes for a subset of NSCLC patients [35].